These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 38905941)
1. Safer-use strategies in the context of harm-reduction treatment for people experiencing homelessness and alcohol use disorder. Alawadhi YT; Shinagawa E; Taylor EM; Jackson C; Fragasso A; Howard M; Fan L; Kolpikova E; Karra S; Frohe T; Clifasefi SL; Duncan MH; Collins SE Int J Drug Policy; 2024 Jul; 129():104448. PubMed ID: 38905941 [TBL] [Abstract][Full Text] [Related]
2. Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial. Collins SE; Duncan MH; Saxon AJ; Taylor EM; Mayberry N; Merrill JO; Hoffmann GE; Clifasefi SL; Ries RK Lancet Psychiatry; 2021 Apr; 8(4):287-300. PubMed ID: 33713622 [TBL] [Abstract][Full Text] [Related]
3. Randomized controlled trial of harm reduction treatment for alcohol (HaRT-A) for people experiencing homelessness and alcohol use disorder. Collins SE; Clifasefi SL; Nelson LA; Stanton J; Goldstein SC; Taylor EM; Hoffmann G; King VL; Hatsukami AS; Cunningham ZL; Taylor E; Mayberry N; Malone DK; Jackson TR Int J Drug Policy; 2019 May; 67():24-33. PubMed ID: 30851620 [TBL] [Abstract][Full Text] [Related]
4. Jail and Emergency Department Utilization in the Context of Harm Reduction Treatment for People Experiencing Homelessness and Alcohol Use Disorder. Collins SE; Goldstein SC; Suprasert B; Doerr SAM; Gliane J; Song C; Orfaly VE; Moodliar R; Taylor EM; Hoffmann G J Urban Health; 2021 Feb; 98(1):83-90. PubMed ID: 33185824 [TBL] [Abstract][Full Text] [Related]
5. Impact of Harm Reduction Treatment with or without Pharmacotherapy on Polysubstance Use among People Experiencing Homelessness and Alcohol Use Disorder. Mostofi N; Collins SE J Addict Med; 2023 Sep-Oct 01; 17(5):574-579. PubMed ID: 37788612 [TBL] [Abstract][Full Text] [Related]
6. Safer-drinking strategies used by chronically homeless individuals with alcohol dependence. Grazioli VS; Hicks J; Kaese G; Lenert J; Collins SE J Subst Abuse Treat; 2015 Jul; 54():63-8. PubMed ID: 25690515 [TBL] [Abstract][Full Text] [Related]
7. Harm reduction treatment for smoking (HaRT-S): findings from a single-arm pilot study with smokers experiencing chronic homelessness. Collins SE; Nelson LA; Stanton J; Mayberry N; Ubay T; Taylor EM; Hoffmann G; Goldstein SC; Saxon AJ; Malone DK; Clifasefi SL; Okuyemi K; Subst Abus; 2019; 40(2):229-239. PubMed ID: 30924732 [No Abstract] [Full Text] [Related]
8. Dual study describing patient-driven harm reduction goal-setting among people experiencing homelessness and alcohol use disorder. Fentress TSP; Wald S; Brah A; Leemon G; Reyes R; Alkhamees F; Kramer M; Taylor EM; Wildhood M; Frohe T; Duncan MH; Clifasefi SL; Collins SE Exp Clin Psychopharmacol; 2021 Jun; 29(3):261-271. PubMed ID: 34264737 [TBL] [Abstract][Full Text] [Related]
9. Harm reduction with pharmacotherapy for homeless people with alcohol dependence: protocol for a randomized controlled trial. Collins SE; Saxon AJ; Duncan MH; Smart BF; Merrill JO; Malone DK; Jackson TR; Clifasefi SL; Joesch J; Ries RK Contemp Clin Trials; 2014 Jul; 38(2):221-34. PubMed ID: 24846619 [TBL] [Abstract][Full Text] [Related]
10. Extended-release naltrexone and harm reduction counseling for chronically homeless people with alcohol dependence. Collins SE; Duncan MH; Smart BF; Saxon AJ; Malone DK; Jackson TR; Ries RK Subst Abus; 2015; 36(1):21-33. PubMed ID: 24779575 [TBL] [Abstract][Full Text] [Related]
11. "There is a Place": impacts of managed alcohol programs for people experiencing severe alcohol dependence and homelessness. Pauly B; Brown M; Evans J; Gray E; Schiff R; Ivsins A; Krysowaty B; Vallance K; Stockwell T Harm Reduct J; 2019 Dec; 16(1):70. PubMed ID: 31842903 [TBL] [Abstract][Full Text] [Related]
12. Qualitatively and quantitatively evaluating harm-reduction goal setting among chronically homeless individuals with alcohol dependence. Collins SE; Grazioli VS; Torres NI; Taylor EM; Jones CB; Hoffman GE; Haelsig L; Zhu MD; Hatsukami AS; Koker MJ; Herndon P; Greenleaf SM; Dean PE Addict Behav; 2015 Jun; 45():184-90. PubMed ID: 25697724 [TBL] [Abstract][Full Text] [Related]
13. Extended-release Naltrexone Is Not Linked to Hepatotoxicity in Adults Experiencing Homelessness and Alcohol Use Disorder. Vutien P; Kim NJ; Merrill JO; Duncan MH; Ioannou GN; Collins SE J Addict Med; 2023 May-Jun 01; 17(3):363-366. PubMed ID: 37267194 [TBL] [Abstract][Full Text] [Related]
14. Investigating the need for alcohol harm reduction and managed alcohol programs for people experiencing homelessness and alcohol use disorders in Scotland. Carver H; Parkes T; Browne T; Matheson C; Pauly B Drug Alcohol Rev; 2021 Feb; 40(2):220-230. PubMed ID: 33006255 [TBL] [Abstract][Full Text] [Related]
15. Non-beverage alcohol consumption among individuals experiencing chronic homelessness in Edmonton, Canada: a cross-sectional study. Westenberg JN; Kamel MM; Addorisio S; Abusamak M; Wong JSH; Outadi A; Jang KL; Krausz RM Harm Reduct J; 2021 Oct; 18(1):108. PubMed ID: 34657618 [TBL] [Abstract][Full Text] [Related]
16. On the outside looking in: Finding a place for managed alcohol programs in the harm reduction movement. Ivsins A; Pauly B; Brown M; Evans J; Gray E; Schiff R; Krysowaty B; Vallance K; Stockwell T Int J Drug Policy; 2019 May; 67():58-62. PubMed ID: 30959410 [TBL] [Abstract][Full Text] [Related]
17. Motives for alcohol use, risky drinking patterns and harm reduction practices among people who experience homelessness and alcohol dependence in Montreal. Motta-Ochoa R; Incio-Serra N; Brulotte A; Flores-Aranda J Harm Reduct J; 2023 Feb; 20(1):22. PubMed ID: 36829166 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials. Falk DE; O'Malley SS; Witkiewitz K; Anton RF; Litten RZ; Slater M; Kranzler HR; Mann KF; Hasin DS; Johnson B; Meulien D; Ryan M; Fertig J; JAMA Psychiatry; 2019 Apr; 76(4):374-381. PubMed ID: 30865232 [TBL] [Abstract][Full Text] [Related]